SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is surging as investors react to a significant earnings beat and raised guidance, highlighting the company's growing role as a critical partner in the AI infrastructure and memory stack. Community sentiment is high, with active discussions focused on its strategic positioning within the NVIDIA ecosystem and the potential for a sustained multi-year growth cycle.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is experiencing high volatility as investors weigh stronger-than-expected revenue guidance against the company's decision to launch a 75 million share offering. Community discussion is sharply divided between long-term supporters viewing the capital raise as a necessary step to secure government manufacturing loans and frustrated traders criticizing management for diluting shares and stalling positive price momentum.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is experiencing a sharp surge in price driven by a strategic 380-megawatt clean power agreement for data centers and the securing of a non-dilutive $49 million financing package from the U.S. Export-Import Bank. The community is actively discussing the stock's transition into momentum mode, with long-term shareholders debating whether this growth signals a sustained reversal or a familiar cycle of dilution and volatility.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as momentum builds around its GLP-1/GIP obesity pipeline, with community members actively discussing a potential buyout or major partnership as institutional accumulation appears to intensify. Investors are eagerly front-running key upcoming clinical data readouts, fueling speculation about the stock's ability to challenge its 52-week highs and capture significant market share.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is seeing intense community speculation and active trading volume driven by persistent buyout rumors and strategic shifts, including the closure of its internal discovery center to focus on capital-efficient partnerships. Traders are closely monitoring short interest and recent technical momentum, as investors weigh potential M&A scenarios against the company's long-term commercial execution.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is gaining significant momentum as investors anticipate the final Phase 3 durability data for its COMP360 treatment, which is critical for an upcoming FDA NDA submission. The community is actively debating the stock's potential for a major re-rating, fueled by recent board appointments, executive-level optimism about commercialization, and the broader institutional rotation into biotech stocks with significant clinical catalysts.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is trending following the FDAs accelerated approval of its lead drug, TRUTAKNA (atacicept), for the treatment of adults with primary IgA nephropathy. While the community is debating the muted post-approval price action, investors remain focused on the drug's commercial potential as the first dual BAFF/APRIL inhibitor in a competitive market.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ouster is gaining strong market momentum as it secures federal compliance under the Build America, Buy America Act, enabling its Rev8 lidar sensors to be deployed across critical U.S. infrastructure projects. Community discussions are highly bullish, with many investors focusing on the company's deepening integration into the physical AI and robotics supply chain through strategic partnerships, viewing recent volatility as a healthy consolidation before a potential move toward higher valuation targets.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

Joby Aviation is attracting significant attention as investors react to its new joint manufacturing venture with Toyota and ongoing FAA certification progress for its electric air taxi. The community is actively debating the stock's potential as a long-term asymmetric play while navigating volatility, with many traders focused on critical support levels and the company's capital runway as it pushes toward commercialization.

American Bitcoin Corp. engages in the management of a bitcoin accumulation platform. It offers exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded by Eric Trump and Donald John Trump Jr. on October 3, 2018 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

American Bitcoin Corp. is experiencing intense community scrutiny and volatility, driven by a proposed reverse stock split and ongoing debates regarding the company's association with the Trump family and its financial management. Investors are actively discussing the stock's significant decline from its highs, questioning the firm's operational transparency, and debating the potential impact of legislative developments like the Clarity Act on its future performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocks making the biggest moves midday: SpaceX, GE Vernova, Crinetics Pharmaceuticals, Rivian & more

Here are some of the companies making headlines in midday trading...

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Crinetics Pharmaceuticals (NASDAQ:CRNX) shares moved upwards by 98.7% to $83.53 during Tuesday's regular session. The company's market cap stands at $4.4 billion.
Tvardi Therapeutics (NASDAQ:TVRD)read more...

Tuesday Sector Leaders: Drugs, Gas Utilities

In trading on Tuesday, drugs shares were relative leaders, up on the day by about 2%. Leading the group were shares of Crinetics Pharmaceuticals, up about 98.8% and shares of Pyxis Oncology up about 18.7% on the day.

Also showing relative strength are gas utilities shares, up...

Crinetics Acquisition Creates A ‘Fifth Commercial Pillar’ For Vertex, Says Analyst – Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock  

Equity

H.C. Wainwright said Crinetics’ lead product Palsonify adds a meaningful commercial product and establishes endocrinology as Vertex’s fifth major business pillar.

VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout 

Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $4.4 billion.
Bluejay Diagnosticsread more...

Stocks making the biggest moves premarket: Fiserv, Crinetics Pharmaceuticals, Micron & more

These are the stocks posting the largest moves in early trading...

Why Crinetics Pharmaceuticals Shares Are Trading Higher By 99%; Here Are 20 Stocks Moving Premarket

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) rose in pre-market trading after being acquired by Vertex Pharmaceuticals (NASDAQ: VRTX) for $85/share.read more...

SLS Stock Rises Overnight: Why Retail Traders Prefer Sellas Over IBRX, ONDS, PYPL As Most Bullish Pick

Traders are watching for the 80th event, data lock and topline results, while some are also speculating about potential M&A.

CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition

The deal values Crinetics at $85 per share in cash, representing a potential upside of about 100% from the stock’s closing price on Monday.


Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Investors are celebrating as Vertex Pharmaceuticals moves to acquire the company for $85 per share in a massive $10 billion all-cash deal.

Traders are now focused on the stock as a pure merger arbitrage play, trading just cents below the $85 cash buyout price ahead of a Q3 2026 close.

The massive 102% buyout premium is fueling a broader rally in the biotech sector, with enthusiasts speculating on which undervalued stock will be the next acquisition target.

Current Price	$83.53
Prev Close	$42.03
Open	$83.58
Dividend Yield	0.00%
50-Day Moving Average	$36.84
Beta	1.18
Avg. Volume	1.24M
PE Ratio	-8.19

52-Week High	$57.99
52-Week Low	$25.83
Market Capitalization	$4.43B
EPS (Annual)	-$4.95
Price to Book	3.46
Revenue Per Employee	$12,956.23

Feed

News

Sentiment

Earnings

Fundamentals

Info

CRNXCrinetics Pharmaceuticals Inc

Latest CRNX News